论文部分内容阅读
目的:探讨恩替卡韦辅助治疗对原发性肝癌经肝动脉化疗栓塞术(TACE)患者的疗效及对患者生存质量、肝功能和免疫功能影响。方法:选择嘉兴市第二医院2017年1月至2018年12月收治的原发性肝癌患者120例，依据随机数字表法分为观察组60例与对照组60例。对照组患者行TACE术治疗，观察组在对照组基础上联合恩替卡韦治疗。两组均以4周为1个疗程，连续治疗3个疗程。比较两组近期疗效、治疗前后Karnofsky功能状态(KPS)评分、肝功能和免疫功能变化。结果:观察组总有效率(71.67%)高于对照组(50.00%)(χn 2＝5.911，n P<0.05)。观察组治疗后KPS评分[(84.25±3.67)分]高于对照组[(75.58±3.29)分](n t＝13.626，n P<0.05)。观察组治疗后谷丙转氨酶(ALT)[(35.42±6.24)U/L]、总胆红素(TBIL)[(23.37±2.89)μmol/L]、谷草转氨酶(AST)[(37.29±4.23)U/L]均低于对照组[(52.29±4.56)U/L、(30.73±3.78)μmol/L、(54.35±3.89)U/L](n t＝16.908、11.982、22.995，均n P<0.05)。观察组治疗后CDn 3+[(58.71±2.93)%]、CDn 4+/CDn 3+[(39.74±3.45)%]、CDn 4+/CDn 8+(1.65±0.39)，高于对照组[(49.63±3.10)%、(31.12±2.13)%、(0.93±0.17)](n t＝16.489、16.468、13.109，均n P<0.05)。n 结论:恩替卡韦辅助治疗对原发性肝癌TACE患者疗效良好，且可改善患者生存质量、肝功能和免疫功能。“,”Objective:To investigate the effect of entecavir combined with transcatheter arterial chemoembolization (TACE) on the quality of life, liver function and immune function of patients with primary liver cancer.Methods:From January 2017 to December 2018, 120 patients with primary liver cancer admitted to the Second Hospital of Jiaxing were randomly divided into observation group(60 cases) and control group(60 cases). The patients in the control group were treated with TACE, while those in the observation group were treated with entecavir on the basis of the control group.Both two groups were treated for 3 consecutive courses, and 4 weeks as a course of treatment.The short-term effect, KPS score, liver function and immune function of the two groups were compared before and after treatment.Results:The total effective rate of the observation group(71.67%) was higher than that of the control group(50.00%)(χn 2=5.911, n P<0.05). The KPS score of the observation group was (84.25±3.67)points, which was higher than that of the control group[(75.58±3.29)points](n t=13.626, n P<0.05). After treatment, the levels of ALT [(35.42±6.24)U/L], TBIL [(23.37±2.89)μmol/L] and AST [(37.29±4.23)U/L] in the observation group were lower than those in the control group [(52.29±4.56)U/L, (30.73±3.78)μmol/L and (54.35±3.89)U/L](n t=16.908, 11.982, 22.995, all n P<0.05). The CDn 3+ [(58.71±2.93)%], CDn 4+ /CDn 3+ [(39.74±3.45)%] and CDn 4+ /CDn 8+ (1.65±0.39) in the observation group were higher than those in the control group [(49.63±3.10)%, (31.12±2.13)% and (0.93±0.17)] (n t=16.489, 16.468, 13.109, all n P<0.05).n Conclusion:Entecavir combined with TACE is effective in the treatment of primary liver cancer, and it can improve the quality of life, liver function and immune function.